financetom
Business
financetom
/
Business
/
Oculis Q2 Loss Narrows
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Oculis Q2 Loss Narrows
Aug 21, 2025 2:42 PM

05:08 PM EDT, 08/21/2025 (MT Newswires) -- Oculis (OCS) reported a Q2 loss late Thursday of 0.49 Swiss francs ($0.61) per diluted share, narrower than a loss of 0.51 francs a year earlier.

A single analyst polled by FactSet expected 0.41 francs per share.

As expected, the company reported no revenue for the period ended June 30.

Grant income was 261,000 francs, up from 245,000 francs a year earlier.

Oculis said it had 160.3 million francs ($201.3 million) in cash, cash equivalents and short-term investments at June 30, up from 98.7 million francs at the end of 2024. The company added that the balance is expected to cover its obligations for at least the next 12 months.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Rock Tech Lithium, Ronbay Technology to Develop Battery Materials Partnership in Europe
Rock Tech Lithium, Ronbay Technology to Develop Battery Materials Partnership in Europe
Jun 26, 2025
07:23 AM EDT, 06/26/2025 (MT Newswires) -- Rock Tech Lithium ( RCKTF ) on Thursday said it has signed a memorandum of understanding with Chinese company Ronbay Technology, which specializes in cathode active materials (CAM), to create a lithium-ion battery materials supply chain in Europe. Rock Tech will sell battery-grade lithium hydroxide to Ronbay's European cathode production facilities in Poland,...
I-Mab Says Givastomig Combination Achieves Rapid, Durable Response in Gastric Cancer
I-Mab Says Givastomig Combination Achieves Rapid, Durable Response in Gastric Cancer
Jun 26, 2025
07:22 AM EDT, 06/26/2025 (MT Newswires) -- I-Mab ( IMAB ) said Thursday that initial data from a phase 1b dose escalation study showed that givastomig with immunochemotherapy for metastatic gastric cancer achieved rapid responses that deepened over time in tumors with low PD-L1 and/or low Claudin 18.2 expression. The company said objective response rates of 71% and 83% were...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Pfizer's Hympavzi Meets Primary Endpoint in Phase 3 Trial for Hemophilia A, B Treatment
Pfizer's Hympavzi Meets Primary Endpoint in Phase 3 Trial for Hemophilia A, B Treatment
Jun 26, 2025
07:22 AM EDT, 06/26/2025 (MT Newswires) -- Pfizer ( PFE ) said Thursday that its phase 3 trial met the primary endpoint with Hympavzi reducing annualized bleed rates by 93% in patients with hemophilia A or B with inhibitors compared to prior on-demand treatment. In the 48-patient study, the annualized bleeding rate dropped to 1.39 with Hympavzi from 19.78 on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved